-like signature in triple negative breast cancer: molecular and clinical characterization reveals subgroups with therapeutic potential

Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10–15% are mutant for the tumor suppressor, BRCA1. BRCA1 is required for homologous recombination-mediated DNA repair and deficiency results in genomic instability. BRCA1-mutated tumors have a specific pattern of genomic copy number aberrations that can be used to classify tumors as BRCA1-like or non-BRCA1-like. BRCA1 mutation, promoter methylation, BRCA1-like status and genome-wide expression data was determined for 112 TN breast cancer samples with long-term follow-up.

Source: Molecular Oncology - May 6, 2015 Category: Cancer & Oncology Authors: Tesa M. Severson, Justine Peeters, Ian Majewski, Magali Michaut, Astrid Bosma, Philip C. Schouten, Suet-Feung Chin, Bernard Pereira, Mae A. Goldgraben, Tycho Bismeijer, Roelof J.C. Kluin, Jettie J.F. Muris, Karin Jirström, Ron M. Kerkhoven, Lodewyk Wesse Source Type: research